OBJECTIVE: To identify colon cancer patients with occult lymph node metastases. SUMMARY OF BACKGROUND DATA: The prognostic value of regional lymph node (LN) metastases in colorectal cancer patients is well established. The disease recurrences nevertheless experienced by 20% to 30% of the LN negative patients suggest a potential for improvement in current LN diagnostics. We suspect that a subgroup of the patients that are LN negative by routine examination has occult LN metastases that are prognostically relevant. METHODS: To identify these patients we applied ex vivo sentinel lymph node (SLN) mapping to colon cancer patients and analyzed the SLNs by a sensitive peptide nucleic acid clamp PCR (polymerase chain reaction) assay for K-ras mutations, using these mutations as a surrogate marker for tumor cells. RESULTS: SLNs were identified in 158 (96%) of 164 prospectively recruited patients with localized colon cancer. Of the 158 patients with successful SLN mapping, 67 (42%) had K-ras mutations detected in their primary tumors. We analyzed the SLNs from these patients by peptide nucleic acid clamp PCR for K-ras mutations and found mutations in SLNs from 35 (52%) patients. At least one SLN from 14 (70%) of 20 patients with histologically proven regional LN metastases was positive for the K-ras mutation test. Interestingly, 21 (45%) of the 47 patients without known LN metastases had K-ras mutations detected in their SLNs. CONCLUSIONS: Sensitive detection of K-ras mutations in SLNs from colon cancer patients indicates the presence of occult metastases with potential prognostic implications.
OBJECTIVE: To identify colon cancerpatients with occult lymph node metastases. SUMMARY OF BACKGROUND DATA: The prognostic value of regional lymph node (LN) metastases in colorectal cancerpatients is well established. The disease recurrences nevertheless experienced by 20% to 30% of the LN negative patients suggest a potential for improvement in current LN diagnostics. We suspect that a subgroup of the patients that are LN negative by routine examination has occult LN metastases that are prognostically relevant. METHODS: To identify these patients we applied ex vivo sentinel lymph node (SLN) mapping to colon cancerpatients and analyzed the SLNs by a sensitive peptide nucleic acid clamp PCR (polymerase chain reaction) assay for K-ras mutations, using these mutations as a surrogate marker for tumor cells. RESULTS: SLNs were identified in 158 (96%) of 164 prospectively recruited patients with localized colon cancer. Of the 158 patients with successful SLN mapping, 67 (42%) had K-ras mutations detected in their primary tumors. We analyzed the SLNs from these patients by peptide nucleic acid clamp PCR for K-ras mutations and found mutations in SLNs from 35 (52%) patients. At least one SLN from 14 (70%) of 20 patients with histologically proven regional LN metastases was positive for the K-ras mutation test. Interestingly, 21 (45%) of the 47 patients without known LN metastases had K-ras mutations detected in their SLNs. CONCLUSIONS: Sensitive detection of K-ras mutations in SLNs from colon cancerpatients indicates the presence of occult metastases with potential prognostic implications.
Authors: Satu Oltedal; Ole Gunnar Aasprong; Jannicke H Møller; Hartwig Kørner; Bjørnar Gilje; Kjersti Tjensvoll; Elke M Birkemeyer; Reino Heikkilä; Rune Smaaland; Oddmund Nordgård Journal: Int J Colorectal Dis Date: 2011-05-15 Impact factor: 2.571
Authors: Marianne Berg; Marianne Guriby; Oddmund Nordgård; Bjørn S Nedrebø; Terje C Ahlquist; Rune Smaaland; Satu Oltedal; Jon Arne Søreide; Hartwig Kørner; Ragnhild A Lothe; Kjetil Søreide Journal: Mol Med Date: 2013-09-10 Impact factor: 6.354
Authors: Kjetil Søreide; Martin M Watson; Dordi Lea; Oddmund Nordgård; Jon Arne Søreide; Hanne R Hagland Journal: J Transl Med Date: 2016-06-29 Impact factor: 5.531